ArticleBrain, behavior, and immunity2025
Executive function and soluble urokinase-type plasminogen activator receptor (suPAR): a longitudinal study of midlife adults.
Article in Brain, behavior, and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) as a Biomarker of Neurodysfunction.Neuromolecular medicine · 2026Review
- Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts 28-Day and 90-Day Mortality in Emergency Department Patients with Chest Pain, Dyspnoea, or Abdominal Pain.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Executive function (EF) declines with age. Declines in EF are associated with adverse outcomes, but there is substantial inter-individual variability in rate and magnitude of decline. Evidence suggests that systemic inflammation may contribute to declines in EF. Extant studies are largely cross-sectional and examine markers of inflammation that are not specific to the immune system and influenced by acute contemporaneous factors. We examined a newer marker of chronic inflammation, soluble urokinase Plasminogen Activator Receptor (suPAR) alongside more traditional markers, IL-6 and CRP. We hypothesized that higher baseline and greater increases in suPAR across an 8-19 (median 17) year period of midlife would associate with larger age-related declines in EF. Data were drawn from the Adult Health and Behavior (AHAB) study (n=599). Participants (55.5% female, 86.2% white, mean age 45 years at W1 and 60 years at W2) completed a neuropsychological battery and blood draw at both waves. EF was comprised of the Trail Making Test, the STROOP Test, and Matrix Reasoning. Univariate and Bivariate Latent change score models (LCSM) examined whether baseline and change in circulating levels of inflammatory mediators were associated with change in EF from W1 to W2. Baseline inflammation was not associated with change in EF. Increases in suPAR were significantly related to concomitant declines in EF (= -0.315; p <.05). No similar effects were observed for IL6 or CRP. Further research should examine suPAR as potential marker of chronic systemic inflammation and its relationship to cognitive aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.